Analyst
Chief Scientist
Chairman
NRX Pharmaceuticals, Inc. (NRXP)Equibles does not estimate personal net worth.
Jonathan Javitt is recorded as Analyst at Chief Scientist, CEO at NRX Pharmaceuticals, Inc. (NRXP) since October 7, 2024 and Chairman at NRX Pharmaceuticals, Inc. (NRXP). The newest filing on record that lists Jonathan Javitt as CEO at NRX Pharmaceuticals, Inc. (NRXP) is dated February 23, 2026. The newest filing on record that lists Jonathan Javitt as Chairman at NRX Pharmaceuticals, Inc. (NRXP) is dated September 5, 2024. NRX Pharmaceuticals, Inc. reported in an 8-K filed October 11, 2024 that Jonathan Javitt was appointed Interim Chief Executive Officer, effective October 7, 2024. The proxy statement of NRX Pharmaceuticals, Inc. reports total compensation of $630,198 for Jonathan Javitt in fiscal 2023, including a base salary of $602,755. Disclosed compensation is on record for 2 fiscal years. Jonathan Javitt has spoken on 16 earnings calls across 1 company, most recently for NRX Pharmaceuticals, Inc. on August 17, 2026. NRX Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at NRX Pharmaceuticals, Inc. includes Jonathan C. Javitt (CEO, Chairman and Board Member), Stephen Willard (CEO), Bennett Kim (CFO and Board Member) and 7 others.
“Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.”
“Thank you for joining us. the second quarter of 2026 was a major inflection point for our company across multiple key objectives as we advanced our mission to bring hope to valuable patients battling depression and suicidal ideation.”
“The first quarter of 2026 was a productive one for NRX. We made progress on both regulatory pathways for preservative-free ketamine, initiated commercial manufacturing, advanced NRX 101 into a registrational trial, continued to grow the Hope Therapeutics Network, and acquired the Genuro assets.”
“2025 was a pivotal and transformative year for NRX and for its Hope Therapeutic subsidiary. We've advanced each of our programs with a drug approval anticipated for Keterfree over the summer. potential for a drug approval this year for NRX100, and a dramatically expanded opportunity for NRX101.”
“Those are great questions, and a lot of this work, the basic science work, has been done and published by Dr. Josh Brown at Harvard-McLean with a number of others supporting the science.”
“The past several months have been nothing short of exceptional for NREX. We've made vital advances across each of our programs, with free drug approval applications in progress, and our evolving network of interventional psychiatry clinics, Hope Therapeutics, taking place.”
2024-10-07–present
Last confirmed February 23, 2026
Chief Scientist
Analyst
Source not stated
Start not stated–present
Last confirmed September 5, 2024
Start not stated–2023-11-22
Last confirmed by a filing; no departure on record
Start not stated–2022-03-08
Biotechnology · Healthcare
Chairman, CEO
2024-10-07–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | NRX Pharmaceuticals, Inc. (NRXP) | Chairman and Chief Scientist | $602,755 | $630,198 |
| 2022 | NRX Pharmaceuticals, Inc. (NRXP) | Chairman and Chief Scientist | $867,446 | $873,696 |
